Asmaa Qamar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Asmaa Qamar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Jawaria Jabeen
College of Pharmacy, University of Sargodha, Sargodha, Pakistan
1 shared publication - Lechun Lyu
School of Rehabilitation and Yunnan Key Laboratory of Plateau Thermal Medical Rehabilitation and Wellness, Kunming Medical University, Kunming 650500, China
1 shared publication - Malja Rehman
College of Pharmacy, University of Sargodha, Sargodha 40100, Pakistan
1 shared publication - Muhammad Anas
College of Pharmacy, University of Sargodha, Sargodha, Pakistan
1 shared publication - Muhammad Muneeb Khalid
College of Pharmacy, University of Sargodha, Sargodha, Pakistan
1 shared publication - Nabeel Ahmed
Yunnan Key Laboratory of Plateau Thermal Medical Rehabilitation and Wellness, School of Rehabilitation, Kunming Medical University, Kunming 650500, China
1 shared publication
Latest Publications
- 20 February 2026
- Published by Springer Nature in Immunologic Research
- Vol. 74 (1) , 17
Efficacy of chimeric antigen receptor natural killer cells in treatment of ovarian cancer. A meta-analysis of pre-clinical studies
Chimeric antigen receptor (CAR) therapies have expanded beyond T-cells with addition of natural killer (NK) cells. In ovarian cancer, long-term survival remains poor with the rising need for new therapies. Therefore, this meta-analysis evaluated the pre-clinical efficacy of emerging CAR-NK therapies in ovarian cancer models. Following PRISMA-guidelines and registered protocol (PROSPERO, CRD420251131530), literature from PubMed, Web of Science, and Scopus was retrieved till 30-06-2025 for pre-clinical in-vivo studies of CAR-NK therapy in ovarian cancer. Studies without in-vivo components or human CAR-NK were excluded. Primary outcomes were ratio of means (ROM) for tumor burden and median survival ratio (MSR). Data was analyzed in JASP™ and risk of bias (RoB) was determined using SYRCLE’s RoB tool for animal studies. Fourteen experiments (21 CAR-NK groups) were included. CAR-NK significantly reduced tumor burden versus untreated controls (ROM 0.09 [0.03–0.32], p < 0.001) and unmodified/mock NK-cells (ROM 0.18 [0.08–0.42], p < 0.001). Survival was significantly prolonged (MSR 1.67 [1.31–2.14] vs. control; 1.40 [1.08–1.83] vs. unmodified/mock NK, both p < 0.05). Subgroup analyses revealed no significant modifiers, though trends favored mesothelin-targeted and NK-92-based CARs. Limited safety data indicated no cytokine release syndrome or graft-versus-host disease. Small sample size in subgroup analyses and unclear RoB in certain areas are some limitations of this study. However, the pooled estimates were robust to sensitivity analyses and relatively insignificant heterogeneity in survival outcomes could be important for poor long-term survival in ovarian cancers. CAR-NK demonstrates potential pre-clinical efficacy in ovarian cancer models, outperforming naive NK-cells with a consistent survival benefit.
- 20 February 2026
- Published by Springer Nature in Immunologic Research
- Vol. 74 (1) , 17
Efficacy of chimeric antigen receptor natural killer cells in treatment of ovarian cancer. A meta-analysis of pre-clinical studies
Chimeric antigen receptor (CAR) therapies have expanded beyond T-cells with addition of natural killer (NK) cells. In ovarian cancer, long-term survival remains poor with the rising need for new therapies. Therefore, this meta-analysis evaluated the pre-clinical efficacy of emerging CAR-NK therapies in ovarian cancer models. Following PRISMA-guidelines and registered protocol (PROSPERO, CRD420251131530), literature from PubMed, Web of Science, and Scopus was retrieved till 30-06-2025 for pre-clinical in-vivo studies of CAR-NK therapy in ovarian cancer. Studies without in-vivo components or human CAR-NK were excluded. Primary outcomes were ratio of means (ROM) for tumor burden and median survival ratio (MSR). Data was analyzed in JASP™ and risk of bias (RoB) was determined using SYRCLE’s RoB tool for animal studies. Fourteen experiments (21 CAR-NK groups) were included. CAR-NK significantly reduced tumor burden versus untreated controls (ROM 0.09 [0.03–0.32], p < 0.001) and unmodified/mock NK-cells (ROM 0.18 [0.08–0.42], p < 0.001). Survival was significantly prolonged (MSR 1.67 [1.31–2.14] vs. control; 1.40 [1.08–1.83] vs. unmodified/mock NK, both p < 0.05). Subgroup analyses revealed no significant modifiers, though trends favored mesothelin-targeted and NK-92-based CARs. Limited safety data indicated no cytokine release syndrome or graft-versus-host disease. Small sample size in subgroup analyses and unclear RoB in certain areas are some limitations of this study. However, the pooled estimates were robust to sensitivity analyses and relatively insignificant heterogeneity in survival outcomes could be important for poor long-term survival in ovarian cancers. CAR-NK demonstrates potential pre-clinical efficacy in ovarian cancer models, outperforming naive NK-cells with a consistent survival benefit.